Adjuvant interferon alfa for melanoma: new evidence-based treatment recommendations?

Trial Watch: Adoptive cell transfer for anticancer immunotherapy. Oncoimmunology (2014) 0.96

Trial watch: Immunostimulatory cytokines in cancer therapy. Oncoimmunology (2014) 0.95

Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment. J Transl Med (2010) 0.93

Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 0.92

Pancreatic cancer, treatment options, and GI-4000. Hum Vaccin Immunother (2014) 0.82

Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep (2014) 0.82

Pancreatic cancer, treatment options, and GI-4000. Hum Vaccin Immunother (2015) 0.80

Effectiveness of electrochemotherapy after IFN-α adjuvant therapy of melanoma patients. Radiol Oncol (2016) 0.77

Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology (2015) 0.77

Severe Raynaud syndrome induced by adjuvant interferon alfa in metastatic melanoma. Curr Oncol (2010) 0.75

Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma. Oncolytic Virother (2017) 0.75

Probable involvement of p11 with interferon alpha induced depression. Sci Rep (2016) 0.75

Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet (1998) 3.84

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma. J Clin Oncol (2009) 2.63

A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet (2005) 1.60

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol (2003) 1.28

Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol (2002) 1.07

Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03

Evidence-based and interdisciplinary consensus-based German guidelines: systemic medical treatment of melanoma in the adjuvant and palliative setting. Melanoma Res (2008) 0.96

Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges (2008) 0.94

Autoimmunity as a prognostic factor in melanoma patients treated with adjuvant low-dose interferon alpha. Int J Cancer (2007) 0.93

Adjuvant therapy of melanoma: is pegylated interferon alfa-2b what we've been waiting for? Lancet (2008) 0.90

Cutaneous malignant melanoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol (2008) 0.90

New promises in the adjuvant, and palliative treatment of melanoma. Cancer Treat Res (2007) 0.80